Advancing Multi-Specific Drug Conjugates to Combat Tumour Heterogeneity & Resistance
11:45 am - Tuesday 9th March 2027
- Presenting the scientific rationale for a multi-specific targeting agent “PIP” and how it enables broad applicability across solid tumours
- Preclinical development of PIP-drug conjugates, their efficacy and safety, and comparison to clinical benchmarks
- Comparing the data from a single vs multi-targeted approach to highlight the rationale of multi-specific targeting
